Frequent β-Catenin Abnormalities in Bone and Soft-tissue Tumors

Kyoko Iwao,1 Yasuo Miyoshi,1 Gen Nawa,1, 2 Hideki Yoshikawa,3 Takahiro Ochi2 and Yusuke Nakamura1, 4
1Division of Clinical Genetics, Department of Medical Genetics, Biomedical Research Center,
2Department of Orthopedic Surgery, Osaka University Medical School, 2-2 Yamadaoka, Saita-shi, Osaka
565-0871, 3Department of Orthopedic Surgery, Osaka Medical Center for Cancer and Cardiovascular
Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka-shi, Osaka 537-0025, and 4Laboratory of Molecular
Medicine, Human Genome Center, The Institute of Medical Science, The University of Tokyo, 4-6-1
Shirokanedai, Minato-ku, Tokyo 108-8639

We have screened mutations of the β-catenin gene by using the polymerase chain reaction-single
strand conformation polymorphism (PCR-SSCP) method in 62 malignant bone and soft-tissue
tumors, including malignant fibrous histiocytomas (MFHs), osteosarcomas, synovial sarcomas,
liposarcomas, malignant schwannomas, and other types of tumors, as well as 11 benign tumors. β-
Catenin-activating missense mutations were found in two malignant tumors. One found in MFH
occurred at codon 45 and caused an amino acid substitution from serine (one of the GSK3β-
targeted phosphorylation sites) to phenylalanine. The other, detected in synovial sarcoma at codon
32, resulted in an amino acid change from aspartic acid (located adjacent to the phosphorylation
target, serine, encoded by codon 33) to tyrosine. Furthermore, we found accumulation of β-catenin
by western-blotting analysis in 12 of 19 malignant tumors in which we found no mutation involv-
ing exon 3. Our results suggested the possible involvement of β-catenin activation, by β-catenin
gene mutation or alteration of other factor(s), in the formation and/or progression of various
types of bone and soft-tissue tumors.

Key words: β-Catenin — Mutation — Bone tumor — Soft-tissue tumor

Soft-tissue tumors are classified into various histo-
pathological types that include malignant fibrous histiocy-
toma (MFH), synovial sarcoma, liposarcoma, malignant
schwannoma, fibrosarcoma, rhabdomyosarcoma, and lei-
omyosarcoma for malignant tumors, and desmoid tumors,
fibroma, lipoma, and schwannoma for benign tumors.1) In
these tumors, p53 and Rb gene alterations are found at the
frequency of 10 to 40%.2, 4) In addition, amplifications of
c-sis, c-myc, and mdm2, point mutations of H-ras and K-
ras, or adenomatous polyposis coli (APC) mutations have
been reported in some types of tumors.1, 4) In addition, amplifications of
c-sis, c-myc, and mdm2, point mutations of H-ras and K-
ras, or adenomatous polyposis coli (APC) mutations have
been reported in some types of tumors.4) 12)

Dysfunction of the APC gene was shown to contribute to the development of desmoid tumor, one of the com-
monest extra-colonic manifestations in patients with familial adenomatous polyposis (FAP),13, 14) as well as spor-
ad cases.10-12) Hence, the functional activation of β-
catenin caused by APC mutation is considered likely to be
a key step in desmoid formation.15) In addition to APC
alterations, mutations of the β-catenin gene itself were
identified in several percent of colorectal cancers,16-18) in
which stabilized and accumulated mutant β-catenin induces increased Wnt/Wingless signaling through Tcf/

Lef-mediated transcriptional activation.19, 20) In desmoid
tumors, the same mechanism might be involved. How-
ever, it is not known whether or not β-catenin activation
is involved in other types of bone and soft-tissue tumori-
genesis.

Oncogenic transformation induced by β-catenin gene
transfer into NIH3T3 fibroblasts was demonstrated,21) and serum-independent cellular proliferation and morphologi-
cal change were produced in Rat-1 fibroblasts by Wnt-1,
which induces β-catenin activation.22) These results sug-

E-mail: yusuke@ims.u-tokyo.ac.jp
The abbreviations used are: PCR-SSCP, polymerase chain reac-
tion-single strand conformation polymorphism; MFH, malignant
fibrous histiocytoma; APC, adenomatous polyposis coli; FAP, familial adenomatous polyposis.

205
MATERIALS AND METHODS

Tissue samples and DNA extraction  Seventy-three bone and soft-tissue tumors consisting of 62 malignant and 11 benign tumors were obtained from patients who underwent surgical resection at Osaka Medical Center for Cancer and Cardiovascular Diseases (Osaka) or Osaka University Medical School Hospital (Osaka), with informed consent. Diagnoses were based on the histopathology. The 62 malignant tumors included 21 MFHs, eight osteosarcomas, seven each of synovial sarcomas, liposarcomas, and malignant schwannomas, three rhabdomyosarcomas, two each of epithelioid sarcomas, neurofibrosarcomas, and chondrosarcomas, and one each of fibrosarcoma, leiomyosarcoma, and alveolar soft-part sarcoma. The 11 benign tumors consisted of three each of giant cell tumors, lipomas, and schwannomas, one desmoplastic fibroma, and one hemangioma (Table I). Fresh materials of each tumor and corresponding normal tissue (muscle or subcutaneous tissue) were stored at −80°C until DNAs were extracted. High-molecular DNAs of each tumor were extracted from frozen materials as described elsewhere.18)

Table I. Histological Type and Summary of β-Catenin Alterations in Bone and Soft-tissue Tumors

| Histological type      | Number of tumors with β-catenin mutation | Number of tumors with elevated expression of β-catenin |
|------------------------|-----------------------------------------|-------------------------------------------------------|
| Malignant              |                                         |                                                       |
| MFH                    | 1/21                                    | 5/8†                                                 |
| Osteosarcoma           | 0/8                                     | 4/6                                                  |
| Synovial sarcoma       | 1/7                                     | 1/3†                                                 |
| Liposarcoma            | 0/7                                     |                                                       |
| Malignant schwannoma   | 0/7                                     |                                                       |
| Epithelioid sarcoma    | 0/2                                     | 1/2                                                  |
| Neurofibrosarcoma      | 0/2                                     | 0/1                                                  |
| Chondrosarcoma         | 0/2                                     |                                                       |
| Fibrosarcoma           | 0/1                                     |                                                       |
| Leiomyosarcoma         | 0/1                                     |                                                       |
| Alveolar soft-part sarcoma | 0/1                                  |                                                       |
| Total                  | 2/62                                    | 11/20                                                |
| Benign                 |                                         |                                                       |
| Giant cell tumor       | 0/3                                     |                                                       |
| Lipoma                 | 0/3                                     |                                                       |
| Schwannoma             | 0/3                                     |                                                       |
| Desmoplastic fibroma   | 0/1                                     |                                                       |
| Hemangioma             | 0/1                                     |                                                       |
| Total                  | 0/11                                    |                                                       |
| Total                  | 2/73                                    | 11/20                                                |

a) One tumor with mutant β-catenin is included.
b) The tumor with mutant β-catenin is not included.

PCR-SSCP analysis  Using a pair of intronic primers, G-F (5’-CCAGCGTGAGCAATGGAATGTC-3’) and G-R (5’-TGAGCTCGAGTCATTGCATGTAAGG-3’), which flank exon 3, 0.1 µg of genomic DNA of each tumor was amplified. The PCR reaction was performed in a volume of 20 µl using Ex Taq polymerase (Takara, Otsu) as follows; 4 min at 94°C for initial denaturing followed by 35 cycles of 94°C for 30 s, 58°C for 30 s, and 72°C for 30 s, using a GeneAmp PCR system 9600 (Perkin Elmer-Cetus, Norwalk, CT). After PCR amplification, an aliquot of PCR product from each sample was mixed with SSCP-loading buffer and electrophoresed for 12 h in a 5% polyacrylamide gel containing 10% glycerol at 500 volts, with cooling at 4°C. The gel was stained with SYBR GREEN II (FMC Bioproducts, Rockland, ME) and bands were quantitated with the FMBIOII Multiview fluorescent image analyzer (Takara). Aberrant bands were isolated from the gel and recovered DNAs were used for the second PCR reaction.

Sequence analyses of aberrant bands  We determined DNA sequences by using an Applied Biosystems model 373 or 377 DNA sequencer (Perkin Elmer-Cetus) and a Dye Terminator Cycle Sequencing FS Ready Reaction Kit (Applied Biosystems, Foster City, CA). Mutations were confirmed by repeated experiments and Southern hybridization with oligonucleotides corresponding to the mutated DNA sequence.

PCR amplification of the genomic region  Exon 3 and surrounding introns were amplified by PCR with primer pairs C-F (5’-CCAGCGTGAGCAATGGAATGTC-3’) and C-R (5’-TGAGCTCGAGTCATTGCATGTAAGG-3’), which are located at exons 2 and 4, respectively. The conditions were as follows; 4 min at 94°C for initial denaturing followed by 35 cycles of 94°C for 30 s, 58°C for 30 s, and 72°C for 1 min.

Protein analysis for β-catenin  Western-blotting analysis was performed to determine the protein level in tumors for which frozen materials were available, as described previously.19) After electrophoresis of 20 µg of total protein from each tumor tissue in 7.5% polyacrylamide gel, proteins were transferred to polyvinylidene difluoride (PVDF) membrane. β-Catenin and actin were visualized with anti-β-catenin (C19229, Transduction Laboratories, Lexington, KY) and anti-actin (CP01, CALBIOCHEM, Cambridge, MA) monoclonal antibody, respectively, and ECL Western blotting detection reagents (Amersham Life Science, Buckinghamshire, UK).

RESULTS

We screened mutations of exon 3 of the β-catenin gene by PCR-SSCP analysis. Among the 62 malignant and 11 benign tumors tested, aberrant migrations were observed in two tumors, one MFH (T17) and one synovial sarcoma.
Fig. 1. (A) The results of SSCP analysis. Aberrant bands are seen in T17 (MFH) and T105 (synovial sarcoma), as indicated by arrows. (B) Sequence analysis of DNA corresponding to the aberrant fragment (T17 and T105) detected by the SSCP analysis. The nucleotide C (the second letter of codon 45) is changed to T, resulting in an amino acid substitution of Phe (TTT) for Ser (TCT) in T17. In T105, the nucleotide T (the first letter of codon 32) instead of G results in an amino acid substitution from Asp (GAC) to Tyr (TAC).

Fig. 2. Western-blotting analysis of tumors. The histological types are shown in the upper column. Accumulation of β-catenin at the position of full size (MW 92,000), indicated by an arrow, is observed in all tumors except T21, T26, T24, T45, and T111. N, normal control. The blot was controlled for protein loading by stripping the blot and reprobing with an antibody against actin.
(T105), in the SSCP analysis (Fig. 1A). Sequencing analyses of the aberrant band of T17 showed a nucleotide change at codon 45 (TTT for TCT), resulting in amino acid substitution from serine to phenylalanine, and that of T105 revealed an amino acid substitution at codon 32 of tyrosine (TAC) for aspartic acid (GAC) (Fig. 1B). In addition, we screened for interstitial deletions involving exon 3, such as are frequently observed in colorectal cancer without APC mutation, by PCR amplification between exon 2 to 4, but no abnormality was identified (data not shown).

Although the frequency of oncogenic β-catenin gene mutations that lead to accumulation of β-catenin was low, we also performed western-blotting analysis for 20 tumors for which frozen materials were available. We normalized β-catenin expression with respect to actin. Among the 20 tumors (eight MFHs, six osteosarcomas, three synovial sarcomas, two rhabdomyosarcomas, and one epithelioid sarcoma), we detected accumulation of β-catenin in 11 tumors as shown in Fig. 2 and Table I.

**DISCUSSION**

β-Catenin activated by mutation of APC or β-catenin itself is known to form a complex with Tcf/Lef transcriptional factors and to be translocated to the nucleus. Binding of the β-catenin-Tcf/Lef complex to specific DNA sequences of the downstream genes transactivates genes involved in the Wnt/Wingless signal transduction pathway. β-Catenin mutations reported so far in several types of tumors are missense mutations of potentially phosphorylatable residues, i.e., serine (at codons 33, 37, and 45) and threonine (at codon 41), or neighboring sites where amino acid changes may influence the efficiency of phosphorylation or alter the protein structure. In addition, interstitial deletions that cause skipping of exon 3 in the transcript have been found in colorectal tumors without APC mutation. Through coupling with the tumor suppressor APC, which is suspected to function as ubiquitin ligase, degradation of β-catenin starts. Phosphorylation by GSK3β of these serine/threonine residues is important for this coupling. Hence, β-catenin mutated at these residues is supposed to escape degradation, being accumulated in the cytoplasm. The two mutations found in this study are thus considered to lead to oncogenic β-catenin activation that is likely to contribute to the tumor development.

Although the frequency of genetic alterations of the β-catenin gene is low, our western-blotting analysis revealed accumulation of β-catenin in more than half of malignant bone and soft-tissue tumors. Since no known β-catenin-activating mutation was found in these β-catenin-accumulated tumors, our results suggest the presence of an unknown oncogenic activation mechanism(s) of β-catenin that plays a significant role in these tumors. Although the frequency of the β-catenin gene mutation is as low as several percent in colorectal tumors, APC gene mutations, which cause β-catenin stabilization and accumulation, are present in the majority of tumors. In endometrioid ovarian carcinomas, the frequency of accumulation of β-catenin in the tumor was also much higher than that of mutation of the β-catenin gene itself. However, in these tumors, the contribution of APC mutations is likely to be very low. Taken together with the results of previous studies, our results suggest that an unknown mechanism(s) that plays an important role in β-catenin regulation may be involved in the development of a relatively large proportion of bone and soft-tissue tumors.

**ACKNOWLEDGMENTS**

We thank M. Nishijima for her technical assistance. This work was supported in part by a special grant for Strategic Advanced Research on Cancer from the Ministry of Education, Science, Sports and Culture of Japan, and a Research for the Future Program Grant (96L00102) from the Japan Society for the Promotion of Science.

(Received September 10, 1998/Revised November 13, 1998/ Accepted November 26, 1998)
β-Catenin Mutation in Bone and Soft-tissue Tumor

7) Leach, F. S., Tokino, T., Meltzer, P., Burrell, M., Oliner, J. D., Smith, S., Hill, D. E., Sidransky, D., Kinzler, K. W. and Vogelstein, B. p53 mutation and MDM2 amplification in human soft tissue sarcomas. *Cancer Res.*, 53, 2231–2234 (1993).

8) Wilke, W., Maillet, M. and Robinson, R. H-ras-1 point mutations in soft tissue sarcomas. *Mod. Pathol.*, 6, 129–132 (1993).

9) Bohlé, R. M., Brettreich, S., Repp, R., Borkhardt, A., Kosmehl, H. and Altmannsberger, H. M. Single somatic ras gene point mutation in soft tissue malignant fibrous histiocytomas. *Am. J. Pathol.*, 145, 731–738 (1996).

10) Sen-Gupta, S., Van der Luijt, R. B., Bowles, L. V., Meera Khan, P. and Delhanty, J. D. Somatic mutation of APC gene in desmoid tumour in familial adenomatous polyposis. *Lancet*, 342, 552–553 (1993).

11) Palmirrotta, R., Curia, M. C., Esposito, D. L., Valanzano, R., Messerini, L., Ficari, F., Brandi, M. L., Tonelli, F., Mariani-Costantini, R., Battista, P. and Came, A. Novel mutations and inactivation of both alleles of the APC gene in desmoid tumors. *Hum. Mol. Genet.*, 4, 1979–1981 (1995).

12) Alman, B. A., Li, C., Pajerski, M. E., Diaz-Cano, S. and Wolfe, H. J. Increased β-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). *Am. J. Pathol.*, 151, 329–334 (1997).

13) Miyaki, M., Konishi, M., Kikuchi-Yanoshita, R., Enomoto, M., Tanaka, K., Takahashi, H., Muraoka, M., Mori, T., Konishi, F. and Iwama, T. Coexistence of somatic and germ-line mutations of APC gene in desmoid tumors. *Hum. Mol. Genet.*, 4, 1979–1981 (1995).

14) Gurbuz, A. K., Giardiello, F. M., Petersen, G. M., Krush, A. J., Offerhaus, G. J., Booker, S. V., Kerr, M. C. and Hamilton, S. R. Desmoid tumours in familial adenomatous polyposis. *Gut*, 35, 377–381 (1994).

15) Munemitsu, S., Albert, I., Souza, B., Rubinfeld, B. and Polakis, P. Regulation of intracellular β-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. *Proc. Natl. Acad. Sci. USA*, 92, 3046–3050 (1995).

16) Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B. and Kinzler, K. W. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. *Science*, 275, 1787–1790 (1997).

17) Soler, A. P., Johnson, K. R., Wheelock, M. J. and Knudsen, K. A. Rhabdomyosarcoma-derived cell lines exhibit aberrant expression of the cell-cell adhesion molecules N-CAM, N-cadherin, and cadherin-associated proteins. *Exp. Cell Res.*, 208, 84–93 (1993).

18) Iwao, K., Nakamori, S., Kaneyama, M., Imaoka, S., Kinoshita, M., Fukui, T., Ishiguro, S., Nakamura, Y. and Miyoshi, Y. Activation of the β-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. *Cancer Res.*, 58, 1021–1026 (1998).

19) Molenaar, M., Wettering, M., Oosterwegel, M., Peterson-Maduro, J., Goldsive, S., Korinek, V., Roose, J., Destree, O. and Clevers, H. XTcf-3 transcription factor mediates β-catenin-induced axis formation in *Xenopus* embryos. *Cell*, 86, 391–399 (1996).

20) Behrens, J., Kries, J. P., Kühl, M., Bruhn, L., Wedlich, D., Grosschedl, R. and Birchmeier, W. Functional interaction of β-catenin with the transcription factor LEF-1. *Nature*, 382, 638–642 (1996).

21) Whitehead, I., Kirk, H. and Kay, R. Expression cloning of oncogenes by retroviral transfer of cDNA libraries. *Mol. Cell. Biol.*, 15, 704–710 (1995).

22) Young, C. S., Kitamura, M., Hardy, S. and Kitajewski, J. Wnt-1 induces growth, cytosolic beta-catenin, and Tcf/Lef transcriptional activation in Rat-1 fibroblasts. *Mol. Cell. Biol.*, 18, 2474–2485 (1998).

23) Kitaeva, M. N., Grogan, L., Williams, J. P., Dimond, E., Nakahara, K., Hausner, P., DeNobile, J. W., Soballe, P. W. and Kirsch, I. R. Mutations in β-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors. *Cancer Res.*, 57, 4478–4481 (1997).

24) Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E. and Polakis, P. Stabilization of β-catenin by genetic defects in melanoma cell lines. *Science*, 275, 1790–1792 (1997).

25) Korinek, V., Barker, N., Morin, P. J., Wichen, D., Weger, R., Kinzler, K. W., Vogelstein, B. and Clevers, H. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC−/− colon carcinoma. *Science*, 275, 1784–1787 (1997).

26) Yost, C., Torres, M., Miller, J. R., Huang, E., Kimelman, D. and Moon, R. T. The axis-inducing activity, stability, and subcellular distribution of β-catenin is regulated in *Xenopus* embryos by glycogen synthase kinase 3. *Genes Dev.*, 10, 1443–1454 (1996).

27) Miyoshi, Y., Nagase, H., Ando, H., Horii, A., Ichii, S., Nakatsuru, S., Aoki, T., Miki, Y., Mori, T. and Nakamura, Y. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. *Hum. Mol. Genet.*, 1, 229–233 (1992).

28) Palacios, J. and Gamallo, C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. *Cancer Res.*, 58, 1344–1347 (1998).